| 11/13/2026 7:48 AM | Avalo Therapeutics (1534120) Subject FARALLON CAPITAL MANAGEMENT, L.L.C. (909661) Filed by | Form SCHEDULE 13G | |
| 11/10/2026 5:36 AM | Avalo Therapeutics (1534120) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |
| 11/06/2026 8:45 AM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 11/05/2026 12:10 PM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 11/05/2026 7:07 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2026 6:51 AM | Avalo Therapeutics (1534120) Filer | Form 424B5 | |
| 11/05/2026 6:58 AM | Avalo Therapeutics (1534120) Filer | Form S-3ASR | |
| 11/05/2026 6:02 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2026 6:04 AM | Avalo Therapeutics (1534120) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 09/18/2026 3:10 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/19/2026 3:10 PM | Avalo Therapeutics (1534120) Issuer Doyle Mittie (1918845) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for AVTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/19/2026 3:10 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/18/2026 3:18 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/17/2026 3:47 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/17/2026 3:49 PM | Avalo Therapeutics (1534120) Subject Doyle Mittie (1918845) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/17/2026 3:18 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 8:00 AM | Avalo Therapeutics (1534120) Subject Avoro Capital Advisors LLC (1633313) Filed by | Form SCHEDULE 13G/A | |
| 08/14/2026 7:24 AM | Avalo Therapeutics (1534120) Subject Deep Track Capital, LP (1856083) Filed by | Form SCHEDULE 13G/A | |
| 08/10/2026 3:47 PM | Avalo Therapeutics (1534120) Subject Doyle Mittie (1918845) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/07/2026 10:04 AM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 08/07/2026 7:44 AM | Avalo Therapeutics (1534120) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |
| 08/06/2026 9:14 AM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 08/06/2026 6:01 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/06/2026 6:03 AM | Avalo Therapeutics (1534120) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/17/2026 3:01 PM | Avalo Therapeutics (1534120) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 07/06/2026 4:29 PM | Avalo Therapeutics (1534120) Subject MILLENNIUM MANAGEMENT LLC (1273087) Filed by | Form SCHEDULE 13G/A | |
| 07/02/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Jain Rita (1707797) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Lind Kevin Robert (1677036) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Philip Ron M (2063957) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Doyle Mittie (1918845) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/25/2026 4:23 PM | Avalo Therapeutics (1534120) Issuer Philip Ron M (2063957) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/25/2026 4:24 PM | Avalo Therapeutics (1534120) Issuer Philip Ron M (2063957) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/25/2026 4:24 PM | Avalo Therapeutics (1534120) Issuer Doyle Mittie (1918845) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 6:01 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/18/2026 3:29 PM | Avalo Therapeutics (1534120) Subject Commodore Capital LP (1831942) Filed by | Form SCHEDULE 13G | |
| 06/16/2026 6:18 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/12/2026 3:41 PM | Avalo Therapeutics (1534120) Issuer VARKI PAUL (1677896) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/12/2026 3:43 PM | Avalo Therapeutics (1534120) Issuer Riley Jennifer (2047607) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/12/2026 3:36 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 3:19 PM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2026 9:13 AM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
A little-known law has been quietly applied to your savings for years. (Ad) Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor.
If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders.
Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title. Request your free 2026 Gold Guide and learn your options today |
| 05/29/2026 3:37 PM | Avalo Therapeutics (1534120) Subject Deep Track Capital, LP (1856083) Filed by | Form SCHEDULE 13G | |
| 05/26/2026 4:10 PM | Avalo Therapeutics (1534120) Subject Point72 Asset Management, L.P. (1603466) Filed by | Form SCHEDULE 13G | |
| 05/15/2026 5:41 PM | Avalo Therapeutics (1534120) Subject Logos Global Management LP (1792126) Filed by | Form SCHEDULE 13G/A | |
| 05/15/2026 3:31 PM | Avalo Therapeutics (1534120) Subject ORBIMED ADVISORS LLC (1055951) Filed by | Form SCHEDULE 13G/A | |
| 05/15/2026 3:04 PM | Avalo Therapeutics (1534120) Subject BIOTECHNOLOGY VALUE FUND L P (918923) Filed by | Form SCHEDULE 13G/A | |
| 05/15/2026 9:31 AM | Avalo Therapeutics (1534120) Subject Caligan Partners LP (1727492) Filed by | Form SCHEDULE 13G/A | |
| 05/15/2026 9:06 AM | Avalo Therapeutics (1534120) Subject | Form SCHEDULE 13G | |
| 05/15/2026 7:15 AM | Avalo Therapeutics (1534120) Subject Avoro Capital Advisors LLC (1633313) Filed by | Form SCHEDULE 13G | |
| 05/13/2026 6:00 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/13/2026 6:02 AM | Avalo Therapeutics (1534120) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/12/2026 5:09 PM | Avalo Therapeutics (1534120) Subject TCG Crossover GP II, LLC (1969280) Filed by | Form SCHEDULE 13G | |
| 05/11/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:18 PM | Avalo Therapeutics (1534120) Issuer VARKI PAUL (1677896) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:20 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:54 PM | Avalo Therapeutics (1534120) Subject Doyle Mittie (1918845) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:29 PM | Avalo Therapeutics (1534120) Subject Chan Mitchell (1789335) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:30 PM | Avalo Therapeutics (1534120) Subject VARKI PAUL (1677896) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:32 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 10:00 AM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 04/29/2026 3:33 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 6:01 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/08/2026 3:51 PM | Avalo Therapeutics (1534120) Issuer Doyle Mittie (1918845) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/06/2026 3:34 PM | Avalo Therapeutics (1534120) Subject Doyle Mittie (1918845) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/03/2026 2:13 PM | Avalo Therapeutics (1534120) Issuer Doyle Mittie (1918845) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/03/2026 2:14 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 3:48 PM | Avalo Therapeutics (1534120) Subject Sullivan Christopher Ryan (1810417) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/01/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Lind Kevin Robert (1677036) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Jain Rita (1707797) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 12:02 PM | Avalo Therapeutics (1534120) Subject Logos Global Management LP (1792126) Filed by | Form SCHEDULE 13G | |
| 03/31/2026 3:09 PM | Avalo Therapeutics (1534120) Issuer Goldman Jonathan (2013869) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:09 PM | Avalo Therapeutics (1534120) Issuer Chan Mitchell (1789335) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:10 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:11 PM | Avalo Therapeutics (1534120) Issuer NEIL GARRY ARTHUR (1586785) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:12 PM | Avalo Therapeutics (1534120) Issuer KAPLAN GILLA (1247024) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:12 PM | Avalo Therapeutics (1534120) Issuer KANTOFF AARON (1862734) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/23/2026 6:15 AM | Avalo Therapeutics (1534120) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/23/2026 6:01 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/23/2026 6:02 AM | Avalo Therapeutics (1534120) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/16/2026 3:39 PM | Avalo Therapeutics (1534120) Subject Doyle Mittie (1918845) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/06/2026 9:05 AM | Avalo Therapeutics (1534120) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 03/02/2026 3:20 PM | Avalo Therapeutics (1534120) Issuer NEIL GARRY ARTHUR (1586785) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:22 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:22 PM | Avalo Therapeutics (1534120) Issuer Boyd Taylor (2090172) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:23 PM | Avalo Therapeutics (1534120) Issuer Doyle Mittie (1918845) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:23 PM | Avalo Therapeutics (1534120) Issuer Riley Jennifer (2047607) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 3:48 PM | Avalo Therapeutics (1534120) Subject MILLENNIUM MANAGEMENT LLC (1273087) Filed by | Form SCHEDULE 13G | |
| 02/17/2026 5:13 PM | Avalo Therapeutics (1534120) Subject ORBIMED ADVISORS LLC (1055951) Filed by | Form SCHEDULE 13G/A | |
| 02/17/2026 5:57 AM | Avalo Therapeutics (1534120) Subject BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by | Form SCHEDULE 13G/A | |
| 02/10/2026 3:07 PM | Avalo Therapeutics (1534120) Subject | Form SCHEDULE 13G | |
| 02/10/2026 10:36 AM | Avalo Therapeutics (1534120) Subject SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by | Form SCHEDULE 13G | |
Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks.
A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. See the five stocks Weiss Ratings analysts are watching closely now. |
| 01/30/2026 12:25 PM | Avalo Therapeutics (1534120) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 01/29/2026 6:56 PM | Affinity Asset Advisors, LLC (1773195) Filed by Avalo Therapeutics (1534120) Subject | Form SCHEDULE 13G/A | |
| 01/20/2026 11:15 PM | Avalo Therapeutics (1534120) Filer | Form EFFECT | |
| 01/12/2026 6:53 AM | Avalo Therapeutics (1534120) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Jain Rita (1707797) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 3:05 PM | Avalo Therapeutics (1534120) Issuer Lind Kevin Robert (1677036) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:17 PM | Avalo Therapeutics (1534120) Issuer Sullivan Christopher Ryan (1810417) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:17 PM | Avalo Therapeutics (1534120) Issuer VARKI PAUL (1677896) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:18 PM | Avalo Therapeutics (1534120) Issuer Riley Jennifer (2047607) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |